Shedding a new light on Huntington’s disease: how blood can both propagate and ameliorate disease pathology

[1]  J. Kordower,et al.  Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms , 2019, Acta Neuropathologica.

[2]  L. Tian,et al.  Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial , 2019, JAMA neurology.

[3]  R. Barker,et al.  Platelet abnormalities in Huntington’s disease , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[4]  Y. Hsu,et al.  Insights into GABAAergic system alteration in Huntington's disease , 2018, Royal Society Open Biology.

[5]  E. Wanker,et al.  mHTT Seeding Activity: A Marker of Disease Progression and Neurotoxicity in Models of Huntington's Disease. , 2018, Molecular cell.

[6]  X. Yao,et al.  Blood-derived amyloid-β protein induces Alzheimer’s disease pathologies , 2018, Molecular Psychiatry.

[7]  Jung Hyun Yoo,et al.  Identification of distinct conformations associated with monomers and fibril assemblies of mutant huntingtin , 2018, Human molecular genetics.

[8]  B. Tang.  Unconventional Secretion and Intercellular Transfer of Mutant Huntingtin , 2018, Cells.

[9]  S. Plassmann,et al.  Self-assembly of mutant huntingtin exon-1 fragments into large complex fibrillar structures involves nucleated branching , 2017, bioRxiv.

[10]  Seung-Jae Lee,et al.  Cell-to-cell Transmission of Polyglutamine Aggregates in C. elegans , 2017, Experimental neurobiology.

[11]  F. Cicchetti,et al.  The Evidence for the Spread and Seeding Capacities of the Mutant Huntingtin Protein in in Vitro Systems and Their Therapeutic Implications , 2017, Front. Neurosci..

[12]  L. Pereira de Almeida,et al.  Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases. , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[13]  S. Villeda,et al.  Therapeutic potential of systemic brain rejuvenation strategies for neurodegenerative disease , 2017, F1000Research.

[14]  D. Rubinsztein,et al.  Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies. , 2017, Cold Spring Harbor perspectives in medicine.

[15]  N. Price,et al.  Peripheral huntingtin silencing does not ameliorate central signs of disease in the B6.HttQ111/+ mouse model of Huntington’s disease , 2017, PloS one.

[16]  S. Tabrizi,et al.  Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells , 2017, Scientific Reports.

[17]  M. D'Esposito,et al.  Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease , 2017, Scientific Reports.

[18]  P. Nigrovic,et al.  Revealing the diversity of extracellular vesicles using high-dimensional flow cytometry analyses , 2016, Scientific Reports.

[19]  Yujin E. Kim,et al.  Soluble Oligomers of PolyQ-Expanded Huntingtin Target a Multiplicity of Key Cellular Factors. , 2016, Molecular cell.

[20]  A. Teixeira,et al.  Neuroimmunology of Huntington's Disease: Revisiting Evidence from Human Studies , 2016, Mediators of inflammation.

[21]  H. Ullum,et al.  Transmission of Neurodegenerative Disorders Through Blood Transfusion , 2016, Annals of Internal Medicine.

[22]  Jihwan Song,et al.  Human-to-mouse prion-like propagation of mutant huntingtin protein , 2016, Acta Neuropathologica.

[23]  J. Couet,et al.  Ablation of Potassium-Chloride Cotransporter Type 3 (Kcc3) in Mouse Causes Multiple Cardiovascular Defects and Isosmotic Polyuria , 2016, PloS one.

[24]  R. Nitsch,et al.  Tau pathology-dependent remodelling of cerebral arteries precedes Alzheimer’s disease-related microvascular cerebral amyloid angiopathy , 2016, Acta Neuropathologica.

[25]  S. Humbert,et al.  The Biology of Huntingtin , 2016, Neuron.

[26]  E. Giltay,et al.  Plasma Cytokine Levels in Relation to Neuropsychiatric Symptoms and Cognitive Dysfunction in Huntington's disease. , 2016, Journal of Huntington's disease.

[27]  B. Ganetzky,et al.  Transcellular spreading of huntingtin aggregates in the Drosophila brain , 2015, Proceedings of the National Academy of Sciences.

[28]  Susan T Francis,et al.  Cerebrovascular and blood–brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology , 2015, Annals of neurology.

[29]  S. Tabrizi,et al.  Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. , 2015, The Journal of clinical investigation.

[30]  Eric H Kim,et al.  The Neuropathology of Huntington's Disease. , 2015, Current topics in behavioral neurosciences.

[31]  A. Reiner,et al.  Differential loss of thalamostriatal and corticostriatal input to striatal projection neuron types prior to overt motor symptoms in the Q140 knock-in mouse model of Huntington's disease , 2014, Front. Syst. Neurosci..

[32]  Diego Mantovani,et al.  Mutant huntingtin is present in neuronal grafts in huntington disease patients , 2014, Annals of neurology.

[33]  Danielle A. Simmons,et al.  Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice , 2014, Nature Medicine.

[34]  A. Reiner,et al.  Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice , 2013, Neurobiology of Disease.

[35]  G. Lederkremer,et al.  Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress , 2013, Nature Communications.

[36]  I. Weissman,et al.  Parabiosis in mice: a detailed protocol. , 2013, Journal of visualized experiments : JoVE.

[37]  Mathias Jucker,et al.  Self-propagation of pathogenic protein aggregates in neurodegenerative diseases , 2013, Nature.

[38]  R. Gold,et al.  Hepatic mitochondrial dysfunction in manifest and premanifest Huntington disease , 2013, Neurology.

[39]  Mei Kwan,et al.  Comprehensive Behavioral and Molecular Characterization of a New Knock-In Mouse Model of Huntington’s Disease: zQ175 , 2012, PloS one.

[40]  M. Diamond,et al.  Amyotrophic lateral sclerosis and organ donation: Is there risk of disease transmission? , 2012, Annals of neurology.

[41]  S. Tabrizi,et al.  Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. , 2012, The Journal of clinical investigation.

[42]  Chris C. Tang,et al.  Monitoring Huntington's disease progression through preclinical and early stages. , 2012, Neurodegenerative disease management.

[43]  C. Soto.  Transmissible Proteins: Expanding the Prion Heresy , 2012, Cell.

[44]  E. Masliah,et al.  Bone Marrow Transplantation Confers Modest Benefits in Mouse Models of Huntington's Disease , 2012, The Journal of Neuroscience.

[45]  P. Snyder,et al.  Biological markers of cognition in prodromal Huntington’s disease: A review , 2011, Brain and Cognition.

[46]  P. Hemachandra Reddy,et al.  Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. , 2011, Human molecular genetics.

[47]  A. Reiner,et al.  Genetics and neuropathology of Huntington's disease. , 2011, International review of neurobiology.

[48]  E. Ramos,et al.  Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[49]  Arrate Muñoz-Barrutia,et al.  3D reconstruction of histological sections: Application to mammary gland tissue , 2010, Microscopy research and technique.

[50]  Jeffrey H Kordower,et al.  Differential vulnerability of neurons in Huntington’s disease: the role of cell type‐specific features , 2010, Journal of neurochemistry.

[51]  M. MacDonald,et al.  Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models , 2009, Neurobiology of Disease.

[52]  J. Caviston,et al.  Huntingtin as an essential integrator of intracellular vesicular trafficking. , 2009, Trends in cell biology.

[53]  V. Beneš,et al.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.

[54]  R. Barker,et al.  The current clinical management of Huntington's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[55]  M. Hayden,et al.  A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease , 2008, The Journal of experimental medicine.

[56]  J. Vonsattel,et al.  Neuropathology of Huntington's disease. , 2008, Handbook of clinical neurology.

[57]  L. Herzenberg,et al.  Modern flow cytometry: a practical approach. , 2007, Clinics in laboratory medicine.

[58]  Stephen Naylor,et al.  Mapping the human plasma proteome by SCX-LC-IMS-MS , 2007, Journal of the American Society for Mass Spectrometry.

[59]  D. Bennett,et al.  Biochemical Characterization of Aβ and Tau Pathologies in Mild Cognitive Impairment and Alzheimer's Disease , 2007 .

[60]  D. Bennett,et al.  Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease. , 2007, Journal of Alzheimer's disease : JAD.

[61]  A. Danek,et al.  Aging is associated with increased collagen type IV accumulation in the basal lamina of human cerebral microvessels , 2004, BMC Neuroscience.

[62]  M. MacDonald,et al.  Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. , 2004, Human molecular genetics.

[63]  Ronald Wetzel,et al.  Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. , 2004, Molecular cell.

[64]  E. Simpson,et al.  Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.

[65]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[66]  E A Zemskov,et al.  Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. , 2001, Human molecular genetics.

[67]  C. Blakemore,et al.  N‐Acetylaspartate and DARPP‐32 levels decrease in the corpus striatum of Huntington's disease mice , 2000, Neuroreport.

[68]  Claire-Anne Gutekunst,et al.  Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology , 1999, The Journal of Neuroscience.

[69]  J. DeFelipe.  Types of neurons, synaptic connections and chemical characteristics of cells immunoreactive for calbindin-D28K, parvalbumin and calretinin in the neocortex , 1997, Journal of Chemical Neuroanatomy.

[70]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[71]  A. Parent,et al.  Sparing of striatal neurons coexpressing calretinin and substance P (NK1) receptor in Huntington's disease , 1996, Brain Research.

[72]  A. Parent,et al.  Calretinin-immunoreactive neurons in the human striatum , 1995, Brain Research.

[73]  W. Zidek,et al.  Transmission of hypertension in rats by cross circulation. , 1989, Hypertension.

[74]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.